Vivimed Labs CFO Phaninder Nath P S Resigns Due to Health Reasons Effective Feb 6, 2026
Mr. Phaninder Nath P S has resigned as Chief Financial Officer of Vivimed Labs Limited due to personal health issues. His resignation is effective February 06, 2026. He will also cease to be a Key Managerial Personnel.
The departure of a Chief Financial Officer can have a medium-term impact on financial strategy and operations until a suitable replacement is found and integrated.
The resignation of a key management personnel, while unfortunate, is a routine corporate event. The reason cited is personal health, which does not inherently indicate positive or negative performance of the company.
Vivimed Labs Limited has announced the resignation of its Chief Financial Officer (CFO), Mr. Phaninder Nath P S. The resignation is effective from the close of business hours on February 06, 2026. The reason cited for his departure is personal health issues that have been aggravating.
Mr. Phaninder Nath P S will also cease to be a Key Managerial Personnel (KMP) and Senior Management Personnel (SMP) of the company from the same date. The company has submitted the necessary disclosures as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, along with the resignation letter from Mr. Phaninder Nath P S. The company's registered office is located in Bidar, Karnataka, with its corporate office in Hyderabad, Telangana.
What to do with a filing like this
Vivimed Labs Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vivimed Labs Limited. Read the original for the full detail.